HIV Peptide Vaults for Mucosal and Systemic Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HIV-1 vaccine designs have failed in human trials due to interference with immune responses, inefficient antigen delivery, inability to generate CTL responses at mucosal surfaces, and mutational escape of HIV-1 from vaccine-induced CTL responses.
Innovation Solution
Development of an HIV peptide vault comprising a vault particle complexed with MVP proteins and HIV peptides, including consensus, ancestral, or mosaic sequences, genetically linked or packaged within the vault particle, to enhance immunogenicity and induce systemic and mucosal immunity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If vector-based vaccines (canarypox, adenovirus) are used to deliver HIV-1 protein genes, then antigen delivery is achieved, but immune responses are interfered with due to competition against the vector
Solution Approach 1:
The patent extracts the HIV-1 antigen delivery function from the vector-based system and places it directly into the vault particle structure. The vault particle itself serves as the delivery vehicle, eliminating the need for separate viral vectors (canarypox, adenovirus) that cause immune competition. This separation resolves the contradiction by removing the harmful vector component while preserving the antigen delivery capability.
Solution Approach 2:
The vault particle acts as an intermediary carrier that delivers HIV-1 peptides without requiring viral vectors. The vault particle's unique structure with internal cavities and surface properties allows it to serve as a non-viral intermediary that avoids triggering competitive immune responses while still effectively delivering antigens to target cells.
2Quantity of substance
If conventional vaccine designs are used, then system-wide immunity is achieved, but mucosal CTL responses at transmission surfaces are not generated
Solution Approach 1:
The patent segments the immune response induction into different compartments: systemic immunity through blood-borne vault particles and mucosal immunity through rectal/vaginal vault particle delivery. This segmentation allows each compartment to be optimized independently, with the mucosal route specifically designed to generate CTL responses at transmission surfaces while maintaining systemic protection.
Solution Approach 2:
The patent adds a mucosal dimension to vaccine delivery by administering vault particles through rectal or vaginal routes, in addition to traditional systemic routes. This dimensional expansion enables simultaneous induction of both systemic and mucosal immune responses, addressing the limitation of conventional single-route vaccines.
3Reliability
If HIV-1 vaccine designs advanced to human efficacy trials are used, then immunogenicity is achieved, but mutational escape of HIV-1 from CTL responses occurs
Solution Approach 1:
The patent applies local quality by selecting and presenting specific conserved peptide sequences from HIV-1 that are least susceptible to mutation. The vault particles display these particular peptide sequences on their surface, creating a focused immune response against critical viral regions that maintain functional constraints, thereby reducing the ability of the virus to escape through mutation.
Solution Approach 2:
The patent employs preliminary action by pre-assembling vault particles with conserved HIV-1 peptide sequences before administration. This pre-configuration ensures that the immune system encounters the most immunogenic and mutation-resistant epitopes first, establishing protective CTL responses before the virus can mutate to escape these responses.
Data Source
AI summary
Disclosed herein are compositions comprising HIV peptide vaults, which are vault particles comprising complexes of MVP proteins and one or more HIV peptides bound or genetically linked to one or more MVP proteins or packaged within the internal cavities of the vault particles and methods of using thereof.